Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals' Once-Weekly Insulin GZR4 Completes First Dosing in Phase II Clinical Trial
The Scientific Evaluation from EMA on Marketing Authorisation Application of Gan & Lee Insulin Glargine biosimilar starts upon the Positive Validation Letter
Gan & Lee Pharmaceuticals GZR18 Completes First Dosing in Two Phase IIb Clinical Trials
NMPA Issued IND Clearance for Gan & Lee’s First Monoclonal Antibody GLR1023 Injection
Gan & Lee Pharmaceuticals Successfully Delivers the First Batch of Insulin for Brazilian Emergency Tender
Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
To be a world-class pharmaceutical company with focus on global business development
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
